BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (ROIV) today announced positive results from the induction period of the TUSCANY-2 Phase 2b ...
Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to significantly improve overall survival versus chemotherapy in this patient population DATROWAY also demonstrated a highly ...
BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, ...
The MarketWatch News Department was not involved in the creation of this content. -- Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney ...
– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC – – Trodelvy ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ...
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with ...
Positive full results from the BATURA Phase IIIb trial showed AstraZeneca’s anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated statistically significant and ...
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback